While unpleasant, this side effect is usually temporary and tends to improve as treatment continues
In my clinical experience, many patients who plateau on semaglutide see renewed progress after transitioning to tirzepatide, although individual results vary and treatment decisions should always be guided by a medical provider
Inflammatory markers, while they do tend to rise with weight regain, may not return to their pre-treatment peaks if the regain is partial rather than complete
It may make weight loss more difficult, especially when insulin resistance is also present
If GI symptoms are severe or persistent beyond three weeks at any given dose, consult your healthcare provider rather than pushing to the next escalation level
Tirzepatide Tirzepatide targets two receptors (GLP-1 + GIP)